Latest Tyrosine kinase inhibitors Stories
Speaking at the UK National Stem Cell Network conference in York later today (31 March), Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia (CML) in which a small number of cancer cells persist despite effective therapy thus preventing cure.
While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.
A detailed analysis of lung tumors that became resistant to targeted therapy drugs has revealed two previously unreported resistance mechanisms.
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.
LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd.
SAN DIEGO, Dec.
A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC).